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786-5 Radlofrequency Cetheter Ablation of Ventricular
Tachycardias Using a New Non-Fluoroscopic
Mapping Technique: First Results
J.L.R.M. Smeets 1, S. Ben-Haim 2, L.-M. Rodriguez 1,C. Timmermans 1,
“,J.J. wellen~ I. I A~demjc HOSpitd Maastricht, The Netherlands,
2 TecfrrrlonUniversity F/aifa, /srae/
The results of radiofrequency (RF) catheter (C) ablation of ventricular tachy-
cadias (VT) are still disappointing. This is caused by several factors: RF
creates small lesions, the reentrant circuit can be located Intramurally, posi-
tioning of C may be difficult, not accurate and hard to reproduce. In this study
we used deflectable C which can be located in a low electromagnetic field
using the CartoT”system. In 6 pts (age 2*76) non fluoroscopic mapping was
performed of VToriginating in the left ventricle. Etiology: idiopathic (1 pt) old
myooardial infarction (5 pts: Inferior in 3, anterior in 1 and anterior/inferior in 1
pt). In 4 pfs one, in 1 pt 2 and in another pt 3 VT morphologies were present.
Results: In one pt VT with 3 VT morphologies only an incomplete map
could be made, so no RF energy was applied. In 5 pte a 3 dimensional map
showedearfy breakthrough in the infero-septal (2), Infero-baso septal (2)
and posterior-lateral area (l). FfF-ablation successfully eliminated VT in 4
pts with 1-5 RF applications. In the remaining pt RF could not terminate VT.
Theareaof endocardial (END) breakthrough was broad (>1 cm), whereas in
the others earfiest END activation araa was narrow. One RF procedura was
oompiloated by a AV Block.
Cone/us/ens: 1) In 5/6 pts complete electroanatomical maps of the left
ventricle during VT could be generated. 2) Guiding by the maps 4/5 VT could
be successfully ablated. 3) RFablation was successful in this limited number
of pts if the map showed a relatively small area of END breakthrough.
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El7866 Entrainment Mapping and Radiofrequency Ablation
of Ventricular Tachycardia In Right Ventricular
Dysplasia
K.E. Ellison, P.L. Friedman, LJ. Ganz, W.G. Stevenson. Brigham and
Women’s Hospiral, Boston, MA, USA
Ventricular tachycardias (VTa) in rightventriculardysplasia(RVD) hava not
been well characterized. The purpose of this study was to determine if
entrainment mapping techniques and predictors of successful ablation sites
previously tested for coronary VT apply to RVD. Mapping of 11 VTSin 4 pts
was performed. At60 sites pacing entrainad VTand RFwas applied to assess
acute termination of VT. Sites were classified as Exit, Central/Proximal (CP),
Inner Loop (IL), Outer Loop (OL) and Bystander by entrainment criteria as
previously described.
Site AcuteTerm “/.
Exit 19 4 21
CP 5 2 40
IL 2 1 50
OL 20 4 20
Bystander 14 2 14
RF acutely terminated VT (acute term) at 13 sites. Acute term at an
exit aite waa followed by absence of inducible VT. VT was often inducible
again when awte term occurred at other types of sites. In two pts RF at a
single site abolished two VTa. In one pt VT was abolished by Ieaionsguided
by pacemapping during sinus rhythm. Thus 7 of 11 VTSwere successfully
ablated and no longer inducible at the end of the study. of these 7 VTS,2
were in the RV outflow tract and the other 5 were adjacent to the tricuspid
annulua. One VT was modified to a longer cycle length. Three VTs were
not ablated or modified. In conclusion entrainment mapping techniques are
uaeful for guiding of RF ablation of VT in RVD. A single region can give rise
to more than one morphology of VT.
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m7871 Older Patients in CARE Benefit from Pravastatin
Post Myocardial Infarction
S.J. Lewis, J, Mitchell, C, East, S.P.Glasser, J. Grant, D,E, Johnstone,
S. Ken, R, Letterer, M. Limacher, G.C. Timmis, L. Moye, J. Rouleau,
M.A. Pfefter, F.M.Sacks, E. Braunwald for the CARE Investigators. Pod/and
Cardiovascular Institute, Portland, Oregon, USA, Legacy Research,
Portland, Oragon, USA
Cholesterol and Recurrent Events (CARE) was a secondary prevention trial
evaluating the benefit of aggressive cholesterol lowering with pravastatin
in post Ml patients with average cholesterol (<240 mg/dl), A prospective
eecondary analysis of CARE was to examine the efficacy in a group of older
(>65) patienta with CHD. At baseline there were 3043 younger (Y) patients
s 65 (54.7 mean), 1116older (0) >65 (69.4 mean). Analysis revealed fewer
currant smokers,ever smokers, and diabetes, but more hypertension Inolder
patients**. Baseline lipids were not different: TC (mg/dl) Y 208.8,0 206; LDL
Y 136.8, 0 138.1; HDL Y 38.4, 040.1, and the pravastatin effect on lipids
at 60 months was similar in older verses younger patients: TC Y 175,2, 0
188.1; LDL Y 100.1, 0 93.4; HDL Y 43.3, 044.3. Both Y and O benefit
from treatment showing risk reduction in endpoints as follows: CHD death or
confirmed Ml Y 19% (NS), O 32%*; CABG Y 17% (NS), O 44%*; PTCA Y
25%*, O 12% (NS); CABG + PTCA Y 25%*, O 35%*; CVA Y 22% (NS), O
40% (NS); combined cardiovascular event endpoint, Y 21%*, O 30%”. This
study demonstrates that despite average lipid levels older patients with CHD
show strong benefit fmm lipid treatment with pravastatin, (*significant, p <
0.05, ** significant, p < 0.001)
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Channel Antagonist Use after Myocardial infarction
J. Leitch, P.McElduff, A. Dobson, R. Heller. Urriversityof Newcastle,
Nekvcast/e,Austra/ia
We evaluated the risk of death and repeat myocardial infarction (Ml) asso-
ciated with the use of calcium antagonists (CA) following Ml in a population
based cohort study associated with the MONICA Project. Patients with Ml
were interviewed in hospital and medical records reviewad. The main out-
comes were time to repeat Ml ancf/orcardiac death and all cause mortality.
Risk ratios were adjusted for age, sex, Ml severity, comorbid conditions and
other drug use.
There were 923 patients treated with CA, 1001 treated with p-blockers
(BB) and 1348 using neither BB nor CA at the time of hospital discharga
after suspected Ml from 1988 to 1994. Compared to patienta discharged on
BB, patients discharged on CA were more likely to have another Ml and/or
cardiac death (rick ratio 1.5 95% Cl 1.2-1.9), cardiac death (risk ratio 1.7,
Cl 1.0-2.7) and death from all causes (risk ratio 1.7, Cl 1.1-2.6). Compared
to patienta given neither BB nor CA, patients given diltiazem (risk ratio 1.4,
Cl 1.1-1.7) and nifadipine (risk ratio 1.6, Cl 1.1-2.4) were at increased risk
of recurrent euspected Ml but not of cardiac death (risk ratios 0.9 [0.4-2.1]
and 0.9 [0.8-1.3], respectively)or all cause mortality (risk ratios 1.0 [0.5-2.1]
and 1.0 [0.7-1 .4]). Risks were not substantially altered when patients taking
other cardiac drugs were excluded. The fisk of Ml and/or cardiac death was
1.6 (Cl 1.2-2.1) for patients given CA alone compared to those given only
BB. Thus, these community based data are consistent with the trial evidence
of the relative benefits of BB and CAafter Ml. Whenever possible, BB should
be usad in preference to CA after myocardial infarction.
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~1 Wfithdrawa,~fCa@qxi,,Afterl.ong-termTreatment,
Increases Ischemic Eventa in Peat-Myocardial
infarction Patienta
A.F.M.van den Heuvel, W.H. van Gilst, D.J. van Veldhuisen, R.J.M. de
Vnes, P.H.J.M. Dunselman, J.H, Kingma for the CATS-investigatore,
Groningen, The Netherlands
ACE-inhibition may have anti-ischemic effects, but whether withdrawal of
these druga mayleadto increased (rebound) ischemia, is unknown. We stud-
iad 207 patients (94 patients on captopril, 113patients on placebo). Captopril,
25 mg TID, was started <24 hr after myocardial infarction, One year double
blind medication, was followed by 1 month single-blind placebo treatment.
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Clinical ischemia related events (PTCA, CABG, Ml, unatable AP and death),
and anti-anginal medications were reported affar 1 month placebo. Baseline
parameters were comparable between the groups. During the 1 month sin-
gle blind placebo period, 10 ischemia related events were reported (placabo
n = 1 and captopril n = 9, (–p < 0.05, placebo vs captopril). Anti-anginal
medication was prescribed in 6 (50A)and 13 (14%) patients, resp. (p c 0.05,
placebo vs captopril). It is concluded that, after atopping captopril, more is-
chemic evants and increased use of anti-anginal medication were reported
then in the placebo group, suggesting a rebound phenomenon.
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El7874 Level of Anticoagulation Achieved in Myocardial
Infarction Patienta Following Chronic Administration
of Fixed, Low-Doae Waffarin Therapy: Reaults from
the Coumadin Aspirin Reinfarction Study (CARS)
R.A. Barrington, S. Berkowitz, M. McDougal, C.M. O’Connor, A. Lenger,
P.T.O’Gare, S.L. Kopecky, .LM. Sutton, J. Hairier, R. Lee, J.M. Feyzi,
L. Jett, R.M. Califf, V. Fuster for the CARS Investigators. Duke C/irrica/
Research Institute, Durham, NC, USA
CARS teeted the hypothesis that the combination of aspirin and fixed, low-
doae warfarin would be euperior to aepirin in preventing death, reinfarction
and stroke following a myoeardial infarction (Ml). Patienta wera randomized
3-21 daya post Ml to one of three treatment arms: aspirin l&I mg (Group
A), warfarin 1 mg + aepirin 80 mg (Group B), warfarin 3 mg + aspirin 80 mg
(Group C). Patients received a double loading dose on the first two days.
At each visit (weeka 1-4, 6, 12, every 12) citrated whole blocd was shippad
overnight to a central laboratory where a prothrombin time waa reported
as an International Normalized Ratio (INR). Blinded dose reduction were
made for an INR 23.5 on two consecutive measures. Median (25, 75) INRs
by treatment groups:
Visit GroupA GroupB GroupC
(n= 2835) (n= 2028) (n= 2829)
Week1 1.03(0,99,1.07) 108 (1.01, 1.12) 1.54(1.24,2.17)
Week2 1.03(0.99,1.07) 1.08(1.02,1.12) 1.48(1.20,2.17)
Week3 1.03(0.98,1.07) 1.05(1.01,1.12) 1,38(1.18,1.90)
Week8 1.02(0.98,1.08) 1,05(1.01,11) 1.22(1.10,1.53)
Month12 1.02(0,98,1.08) 1.04(1.00,1.10) 1.20(1.08,1,50)
A steady state INR was reached and maintained by week six with the
majority of patients having INRaconsiderably leas than the standard level of
anticoagulation typically used in clinical practice (INR 2.0+3.0). The low level
of anticoagulation obtained may in part explain the equivalence in outcomes
among the treatment arms in CARS.
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1787-5]lnflUenCeOfHYW~ensionand~,oodpressure~n
the Suwival Benefit of ACE Inhibition After Acute
Myocardial Infarction
L. Kaber, C. Torp-Pedereen, M. Ottesen, H, Burchardt for the TRACE atudy
group. Dept. of Cardiology, Gentofle University Hospital, Denmark
Low blood pressure following an Acuta Myocardial Infarction is a relative
contraindication for ACE inhibition. We studied interrelation of the beneficial
effect of ACE inhibition with blood preasure at start of treatment and a diag-
noeiaof hypertension in the Trandolaprfl Cardiac Evaluation (TRACE) study.
Methods: In TRACE 1749 patients with moderate to aevere left ventricular
dysfunction (wellmotion indexs 1.2)ware randomieedtolong-term treatment
with the ACE inhibitor trandolapril or placebo. Ovarall the mottality reduction
of trandolapril was 22Y0.At randomisation 283 patients had syatolic bled
preasure (SBP) s 100,427 had SBP 101-110,428 had SBP 111-120,459
had SBP 121-140 and 174 had SBP >140. A histoty of hypertension was
present in 400 patients. Calculations are based on Cox propotiional hazard
medals and wall motion index, hearl failure, gender, aga and thrombolysis
are included ad confounding factora in the models. Results:
Subgroup RiskReductionwithTrandolapril
No diagnoaisof hvvarlension 0.9(0.75-1.1)
Diagn;aia of hypitiension 0.8 (OAS-0J35)
SBP <100 1.0 (0.7-1.5)
SBP 101-110 0.S8 (0.85-1.2)
SBP111-120 0.78 (0.55-1.0)
SBP 121-140 0,SS (0.85-1.2)
SSP>140 0.57(0.35-0.92)
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Mortality Rate After Myocardial Infarction Equally
Increaeed in Diabetic Patients Treated with Oral
Antidiabetic Agents and Insulin
P.Hildebrandt,M. Saibek, L. K@ber,C. Torp-Pedereenforthe TRACE
StudyGroup.Dept. of Cardiology Frederiksberg /-fospita/,Denmark, Dept.
of CardioIog~ Gentoffe Hospital, Denmark
Patients with diabetes havea poor prognosis after myocardial infarction (Ml).
However, the relation to different types of diabetic traatment, Ml complica-
tions and residual systolic function is uncertain. The aim of the present study
was a further evaluation of theee relationships. Methods: 5960 patients with
confirmed Ml, surviving 2 days after admission were included in the study.
Preadmission medical history, including type of diabetic treatment, compli-
cations during hoapital stay and echocardiographic evaluation of ventricular
wall motion index (WMI) were obtained, as well as 3 year mortality data.
Resu/fs:% mortality
Non-diabetics Diet Tablets Insulin
Number 5387 173 319 125
1 year 17.0 24.3 29.2 29.6
2 year 23.2 34.3 42.8 41.7
3 year 28.8 41.7 53.7 51.6
By multivariateanalysisincludingage, sex, WMI, historyof hypertension
and perviousMl, diabetea was found to be an independentpradictorof
mortality(oddsratio1.488 (95% Cl: 1.221,814))
Conclusion: Patients with diabetes have a poor prognoais after Ml, with
a significant increased moflality rate, regardless of other risk factors. This
increased morlality is similar in patients treated with insulin and oral anti
diabetics agents.
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Improvement in Stunned and Hibernating
Myocardium in Patients with Coronary Artery
Disease (CAD) and Congestive Heart Failure (CHF)
F.Haas, C. Haehnel, N. Augustin, W. Pickeri, S. Nekolla 1, H. Meisner,
M. Schwaiger. Deutsches Herzzentrum Murrchen, German& 1 Technische
UrriversitatMiinchen, Germany
Ithas been demonstrated that NH3/FDG-positron emission tomography
(PET) predicts the recoveryof regional function of ischemically compromised
myocardium. The present study evaluated the time course and the extant of
improvement of “hibernating myocardium” (flow-metabolism-miamatch; HIB)
and of “stunned myocardium” (normal flow/metabolism but impaired func.
tion; STU). 26 patients with CAD and CHF (EF = 27%) were functionally
assesaad by 2-d echocardiography using a 5-point grading system from -1
(dyskinesia) to 3 (normal function) preoperatively, 10 days, 4 month and
one year after CABG, 213 revascularized free-wall LV-segments with wall
motion abnormalities were examined: 2S.2?4of the segmente displayed HIB,
while the remaining 71.6% STU, TendaysafterCABG 507. of HIB segments
regained normal to near normal function. Four months and one year after
CABG, however, 73.1% and 67% diaplayed this functional improvement. In
contrast, 76.5% of STU aegments regained normal to near normal function
after 10 days (p = 0005), after 4 month 84.8% (p = 0.01) and after 1 year
85.4% (n.a). The results suggast that in patients with marked LV-dysfunction
scintigraphic patterns of “atunning” are more pronounced than that of “hi.
bernation”. Preoperatively, “hibernating myocardium” displays more sevare
wall motion abnormalities with slower recovery; after one yaar, however,
the degree of functional improvement is similar in both aituationa. For early
racovery “stunned myocardium” appears to be more important.
Corrc/uaion:Thebeneficial effect of Trandolaprflseems to be more marked
in patients with a history of hypertension or a relative high blood pressure on
entry.
